Business Wire

SES

Share
SES’s Next-Gen NGSO System Readies for Launch with 8 Initial O3b mPOWER Satellite Ground Stations

SES announced today that it has signed agreements with key infrastructure service providers around the world to build its eight initial O3b mPOWER satellite ground stations. Construction has already started on these advanced technology satellite ground stations, which will become operational in the second half of this year. The eight sites will provide telemetry, tracking and control capabilities to enable SES’s management of the constellation. They will also be leveraged to raise the satellites into the right orbit after the scheduled launches.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427006193/en/

As previously announced, two of the satellite ground stations are located at Dubbo, NSW, Australia (operated by Pivotel) and Thermopylae, Greece (operated by OTE) . Other locations include Merredin, Perth, Australia; Phoenix, Arizona, US; Chile; the United Arab Emirates; Senegal as well as SES’s own satellite ground station in Hawaii. Four out of the eight sites will be co-located and operated with Microsoft’s Azure data centres ; the one-hop connectivity to the cloud from remote sites will provide O3b mPOWER customers the ability to optimise business operations with significant flexibility and agility.

O3b mPOWER is SES’s next-generation Medium Earth Orbit (MEO) system. Building on the success of O3b, each of the 11 high-throughput, low-latency O3b mPOWER satellites will deliver high-speed connectivity services from tens of megabits to multiple gigabits per second, providing fibre-like connectivity to customers globally.

The O3b mPOWER satellite ground stations have many technically advanced features compared to the existing O3b satellite ground station. They include a new generation of fast-install 5.5-metre carbon fibre antennas which can be installed without the need for expensive and time-consuming photogrammetry. In addition, they will utilise energy-efficient solid-state power amplifiers, and a low electrical load for the antenna control unit (ACU).

The satellite ground stations will use SES’s gateway management system for automated operations and handovers, which will be tightly integrated with SES’s unique resource management capability, Adaptive Resource Control (ARC) and other SES software sub-systems. With this configuration, SES will dynamically manage and optimise space and ground resources to meet the changing needs of its customers. These combined technology advances result in improved efficiency and lower total cost of ownership.

The first three O3b mPOWER satellites are scheduled for launch in the third quarter of this year, with the next three in the first quarter of 2022. After orbit raising, O3b mPOWER will start delivering services in the third quarter of 2022.

Stewart Sanders, Executive Vice President of Technology and O3b mPOWER programme manager at SES, said, “We are thrilled to have chosen these eight locations and construction is underway. We are also deep in discussions with several telco players and operators who are keen to have their own O3b mPOWER satellite ground station. This is particularly exciting, as it means that SES’s provision of a core network of command, control and data gateways will be augmented with a number of customer satellite ground stations; satellite ground stations provisioned according to our customer needs, with regards to location, size and infrastructure requirements. We expect a number of these customer satellite ground stations to include virtualised installations of the cloud at the edge of the deployed networks, thus improving the end-user experience.”

Follow us on:

Read our Blogs >

Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye